4,461 results match your criteria cases hbsag


[Clinicopathological analysis in patients with chronic hepatitis B virus infection in immune tolerant phase].

Zhonghua Nei Ke Za Zhi 2021 Oct;60(10):891-897

Ningbo Institute of Liver Diseases, Hwa Mei Hospital, University of Chinese Academy of Sciences (Ningbo No.2 Hospital), Ningbo 315010, China Ningbo Institute of Life and Health Industry, University of Chinese Academy of Sciences, Ningbo 315010, China.

To analyze the liver pathology, clinical characteristics and influence factors in patients with chronic hepatitis B virus (HBV) infection in immune tolerant phase (IT). The clinical data of 273 patients in IT phase who underwent liver biopsy from January 2015 to December 2019 were included in this study. The correlation between liver pathological changes and clinical features was analyzed. Read More

View Article and Full-Text PDF
October 2021

Discontinuation of antiviral therapy in chronic hepatitis B patients.

World J Clin Cases 2021 Aug;9(24):6979-6986

Department of Gastroenterology and Hepatology, Centro Hospitalar Universitário de São João, Porto 4200-319, Portugal.

Nucleos(t)ide analogs (NUC) are the first-line therapy for patients with chronic hepatitis B (CHB) recommended by most current guidelines. NUC therapy decreases progression of liver disease, reduces the risk of liver-related complications, and improves the quality of life of patients with CHB. Although indefinite or long-term NUC therapy is usually recommended, this strategy raises several concerns, such as side-effects, adherence, costs, and patient willingness to stop therapy. Read More

View Article and Full-Text PDF

Analysing "tear-drop" prints of acute promyelocytic leukemia (APML): immunophenotypic prognostication of APML by FCM.

Am J Blood Res 2021 15;11(4):446-457. Epub 2021 Aug 15.

ICMR-National Institute of Pathology, Safdarjung Hospital Campus Ansari Nagar, New Delhi, India.

Introduction: Acute promyelocytic leukemia (APML), although genetically and morphologically distinct from other AML (acute myeloid leukemia) subtypes, is one of the most best responsive acute myeloid leukemia. -Conventional diagnostic methods and morphological hints often fail in the majority of the cases in the peripheral laboratories owing to resource constraints, unavailability of cytogenetic work-up, hypogranular variants, morphological mimicry by AML-monocytic and myelo-monocytic, etc. Flowcytometry (FCM), however, can be utilized as a feasible and reliable immunophenotypic diagnostic and prognostic tool for prompt identification of APML. Read More

View Article and Full-Text PDF

Detection of the serological markers hepatitis B virus surface antigen (HBsAg) and hepatitis B core IgM antibody (anti-HBcIgM) in the diagnosis of acute hepatitis B virus infection after recent exposure.

Microbiol Immunol 2021 Sep 16. Epub 2021 Sep 16.

Laboratory of Human Virology, Institute of Tropical Pathology and Public Health, Federal University of Goiás, Goiânia, Goiás, Brazil.

The serological diagnosis of acute HBV infection after recent exposure has been established by the HBsAg and anti-HBcIgM detection in serum, sometimes accompanied by the detection of HBeAg. Despite this characteristic serological profile, the misdiagnosis can occur in cases of unexpected or atypical behavior of the serological markers in the bloodstream, or if the true meaning of its expression is not properly investigated, or even if there is a possibility of interference from factors not necessarily linked to the infectious process, in the detection of these markers. This review discusses the influence of these variables on laboratory results for these two serological markers and, therefore, the potential risk of these variables compromising the correct diagnosis of acute infection after recent HBV exposure. Read More

View Article and Full-Text PDF
September 2021

Evaluation of hepatitis B virus, hepatitis C virus, and human immunodeficiency virus seroprevalence in patients with diffuse large B cell lymphoma and Hodgkin's lymphoma.

J Cancer Res Ther 2021 Jul-Sep;17(4):951-955

University of Health Sciences, Dr. Abdurrahman Yurtaslan Oncology Training and Research Hospital, Hematology Clinic and Bone Marrow Transplantation Unit, Ankara, Turkey.

Backgrounds: Non-Hodgkin's lymphoma and Hodgkin's lymphomas (HL) are lymphoid neoplasms. Hepatitis B virus (HBV), hepatitis C virus (HCV), and human immunodeficiency virus (HIV) are viruses that could proliferate in lymphoid tissues. These viruses may cause lymphoproliferative diseases. Read More

View Article and Full-Text PDF
September 2021

Auxiliary Liver Graft Can Be Protected From HBV Infection in HBsAg Positive Blood Circulation.

Front Med (Lausanne) 2021 25;8:726502. Epub 2021 Aug 25.

Beijing Friendship Hospital, Capital Medical University, Beijing, China.

Auxiliary grafts have a high risk of Hepatitis B virus (HBV) infection in patients with chronic HBV-related diseases. Hepatitis B virus-related auxiliary partial orthotopic liver transplantation (APOLT) cases were reviewed to show the results of current methods to block native-to-graft HBV transmission. Three patients received APOLT for HBV-related liver cirrhosis and a recurrent upper gastrointestinal hemorrhage between April 2015 and January 2017 by the liver transplant team of Beijing Friendship Hospital affiliated with Capital Medical University. Read More

View Article and Full-Text PDF

Improvement of hepatitis B vaccine to induce IFN-γ cytokine response: A new formulation.

Microb Pathog 2021 Sep 9;160:105184. Epub 2021 Sep 9.

Recombinant Vaccine Research Center, Tehran University of Medical Sciences, Tehran, Iran; Immunotherapy Group, The Institute of Pharmaceutical Sciences (TIPS), Tehran University of Medical Sciences, Tehran, Iran; Department of Immunology, Pasteur Institute of Iran, Tehran, Iran. Electronic address:

Hepatitis B virus (HBV) infection is limited through vaccination against HBsAg formulated in the Alum adjuvant. However, this alum-formulated vaccine fails to be preventive in some cases, also known as non-responders. Recent studies have shown the immunomodulatory effect of α-tocopherol in various models. Read More

View Article and Full-Text PDF
September 2021

High Risk of Viral Reactivation in Hepatitis B Patients with Systemic Lupus Erythematosus.

Int J Mol Sci 2021 Aug 24;22(17). Epub 2021 Aug 24.

Division of Gastroenterology, Department of Medicine, Taipei Veterans General Hospital, Taipei 11217, Taiwan.

HBV reactivation (HBVr) can occur in hepatitis B surface antigen (HBsAg)-positive and negative patients. Here, we determined the incidence of HBVr and its related hepatitis in patients with systemic lupus erythematosus (SLE). From 2000 to 2017, 3307 SLE cases were retrospectively reviewed for episodes of hepatitis. Read More

View Article and Full-Text PDF

Kinetics of quantitative hepatitis B surface antigen in patients with rheumatic disease and chronic hepatitis B receiving biologic agents.

J Viral Hepat 2021 Sep 8. Epub 2021 Sep 8.

Clinical Immunology-Rheumatology Unit, 2nd Department of Medicine and Laboratory, National and Kapodistrian University of Athens School of Medicine, Hippokration General Hospital, Athens, Greece.

The effect of biologic treatment on quantitative Hepatitis B surface Antigen (qHBsAg) levels and HBsAg clearance in rheumatic patients with chronic HBV infection has not been well studied. We prospectively followed rheumatic patients with HBeAg-negative chronic HBV infection (n = 28) treated with biologics and oral antivirals, categorized into patients with chronic hepatitis B (CHB, group A n = 13) and chronic HBV infection (group B n = 15) and matched them to appropriate non-rheumatic controls. qHBsAg kinetics were serially measured and compared between groups. Read More

View Article and Full-Text PDF
September 2021

[Vertical transmission of hepatitis B: the importance of incorporating screening during pregnancy in Chile].

Rev Chilena Infectol 2021 Jun;38(3):401-409

Hospital Regional Hernán Henríquez, Temuco, Chile.

Half of cases of hepatitis B around the world are produced from vertical transmission; and 90% of them can evolve to chronic hepatitis and their long term complications. Postpartum immunoprophylaxis (immunoglobulin and vaccine) is the most effective preventive measure. However, despite this prophylaxis, vertical transmission is possible if the mother presents a high viral load or e-antigen. Read More

View Article and Full-Text PDF

Viral and bacterial factors of mother-to-child transmission of hepatitis B virus.

J Viral Hepat 2021 Sep 1. Epub 2021 Sep 1.

Bacterial and Viral Serology Laboratory of Institut Pasteur, Abidjan, Ivory Coast.

Hepatitis B virus (HBV) infection is the tenth leading cause of death worldwide. Mother-to-child transmission of HBV occurring mainly at delivery remains one of the most common routes of infection in developing countries. One of the main challenges concerning HBV in Africa is to implement a prevention policy aiming at interrupting the cycle of pseudo-vertical transmission of this infection. Read More

View Article and Full-Text PDF
September 2021

Arresting vertical transmission of hepatitis B virus (AVERT-HBV) in pregnant women and their neonates in the Democratic Republic of the Congo: a feasibility study.

Lancet Glob Health 2021 Aug 17. Epub 2021 Aug 17.

Department of Medicine, University of North Carolina, Chapel Hill, NC, USA.

Background: Hepatitis B virus (HBV) remains endemic throughout sub-Saharan Africa despite the widespread availability of effective childhood vaccines. In the Democratic Republic of the Congo, HBV treatment and birth-dose vaccination programmes are not established. We, therefore, aimed to evaluate the feasibility and acceptability of adding HBV testing and treatment of pregnant women as well as the birth-dose vaccination of HBV-exposed infants to the HIV prevention of mother-to-child transmission programme infrastructure in the Democratic Republic of the Congo. Read More

View Article and Full-Text PDF

Prevalence of HBV and HCV infection in beta-thalassemia major patients of Tabriz city, Iran.

New Microbes New Infect 2021 Sep 6;43:100912. Epub 2021 Jul 6.

Department of Microbiology School of Basic Sciences, Kazerun Branch, Islamic Azad University, Kazerun, Iran.

People with beta-thalassemia major are more likely to acquire blood-borne viral infections due to the need for frequent blood transfusions. Of these viruses, hepatitis B virus (HBV) and hepatitis C virus (HCV) are of particular importance. In this study, the prevalence of HBV, HCV and their risk factors in beta-thalassemia major patients in East Azerbaijan province was investigated. Read More

View Article and Full-Text PDF
September 2021

Does Hepatitis B Virus Affect the Coagulation Parameters for HBV-Related Decompensated Cirrhosis?

Clin Lab 2021 Aug;67(8)

Background: To evaluate the effect of the hepatitis B virus (HBV) on the coagulation parameters in patients with hepatitis B virus-related decompensated cirrhosis (HBV-DeCi).

Methods: A retrospective analysis was conducted on the medical records of 112 patients with HBV-DeCi. Baseline clinical and laboratory characteristics were retrieved. Read More

View Article and Full-Text PDF

Detection and Genetic Characterization of Hepatitis B and D Viruses: A Multi-Site Cross-Sectional Study of People Who Use Illicit Drugs in the Amazon Region.

Viruses 2021 07 15;13(7). Epub 2021 Jul 15.

Programa de Pós-Graduação em Biologia Ambiental, Universidade Federal do Pará, Bragança 68600-000, PA, Brazil.

Hepatitis B (HBV) and delta (HDV) viruses are endemic in the Amazon region, but vaccine coverage against HBV is still limited. People who use illicit drugs (PWUDs) represent a high-risk group due to common risk behavior and socioeconomic factors that facilitate the acquisition and transmission of pathogens. The present study assessed the presence of HBV and HBV-HDV co-infection, identified viral sub-genotypes, and verified the occurrence of mutations in coding regions for HBsAg and part of the polymerase in HBV-infected PWUDs in municipalities of the Brazilian states of Amapá and Pará, in the Amazon region. Read More

View Article and Full-Text PDF

[Quantitative hepatitis B core antibody levels can be used as a predictive index of HBsAg clearance].

Zhonghua Gan Zang Bing Za Zhi 2021 Jul;29(7):673-678

Fist Department of Liver Disease Center, Beijing Youan Hospital, Capital Medical University, Beijing 100069, China.

To explore the possibility of hepatitis B core antibody (anti-HBc) in predicting hepatitis B virus surface antigen (HBsAg) clearance. Sixty cases with chronic hepatitis B who were previously treated with peginterferon α-2a combined with nucleos(t)ide analogues (NAs) antiviral therapy were divided according to the HBsAg clearance or non-clearance; 41 cases in the clearance group and 19 cases in the non-clearance group. Double antigen sandwich method was used to detect patients anti-HBc quantitative levels during the course of treatment and at baseline, 24, 48, 72 and 96 weeks. Read More

View Article and Full-Text PDF

[Early reduction of serum RANTES can predict HBsAg clearance in patients with chronic hepatitis B treated with nucleos(t)ide analogues combined with peginterferon alpha].

Zhonghua Gan Zang Bing Za Zhi 2021 Jul;29(7):666-672

Medical School of Chinese PLA, Beijing 100853, China Department of Infectious Diseases, The Fifth Medical Center of Chinese PLA General Hospital, National Clinical Research Center for Infectious Diseases, Beijing 100039, China Peking University 302 Clinical Medical School, Beijing 100039, China.

To observe the dynamic changes of serum RANTES during the treatment with nucleos(t)ide analogues combined with pegylated interferon alpha (peginterferon-α), and further analyze the predictive effect of RANTES on HBsAg clearance in patients with chronic hepatitis B. 98 cases of chronic hepatitis B with quantitative HBsAg < 3 000 IU/ml and HBV DNA < 20 IU/ml after≥1 year NAs treatment were enrolled. Among them, 26 cases continued to receive NAs monotherapy, 72 cases received NAs combined with pegylated interferon alpha therapy. Read More

View Article and Full-Text PDF

Soluble programmed death-1 is predictive of hepatitis B surface antigen loss in chronic hepatitis B patients after antiviral treatment.

World J Clin Cases 2021 Jul;9(21):5812-5821

Department of Infectious Diseases, Peking University First Hospital, Beijing 100034, China.

Background: Hepatitis B surface antigen (HBsAg) loss, a functional cure in patients with chronic hepatitis B (CHB) undergoing antiviral therapy, might be an ideal endpoint of antiviral treatment in clinical practice. The factors that contribute to the functional cure remain unclear, and the predictors of functional cure are worth exploring. The concentration and kinetics of soluble programmed death-1 (sPD-1) in patients with CHB may play an important role in elucidating the immune response associated with functional cure after nucleos(t)ide analogs therapy. Read More

View Article and Full-Text PDF

The role of quantitative HBsAg in the natural history of e antigen-negative chronic hepatitis B: A Tunisian prospective study.

Infect Dis Now 2021 Aug 30;51(5):464-469. Epub 2020 Dec 30.

Faculty of medicine of Monastir, Department of gastroenterology, Fattouma Bourguiba Hospital, Monastir, Tunisia.

Background/aims: During the natural course of Chronic Hepatitis B (CHB) infection, differentiation between inactive carrier (IC) and HBeAg negative CHB is a subject of ongoing debate. We studied the role of hepatitis B surface antigen (HBsAg) level as a means of differentiating between CHB and IC in a group of untreated chronic HBeAg-negative HBV-infected patients.

Study: A total of 115 HBeAg negative carriers were enrolled and followed up for>12 months; 78 as inactive carriers (IC), and 37 as active carriers (AC). Read More

View Article and Full-Text PDF

Long-Term Safety in HBsAg-Negative, HBcAb-Positive Patients with Rheumatic Diseases Receiving Maintained Steroid Therapy after Pulse Therapy.

J Clin Med 2021 Jul 26;10(15). Epub 2021 Jul 26.

Department of Medical Research, Taichung Veterans General Hospital, Taichung 40705, Taiwan.

The risk of hepatitis B virus (HBV) reactivation in hepatitis B surface antigen (HBsAg)-negative, antibody to hepatitis B core antigen (anti-HBc)-positive patients after glucocorticoid (GC) pulse therapy remains unclear.

Aims: Our study aimed to examine the safety of GC pulse therapy in HBsAg-negative, anti-HBc-positive rheumatic patients.

Methods: Medical records of HBsAg-negative, anti-HBc-positive patients receiving GC pulse therapy to treat rheumatic diseases were reviewed. Read More

View Article and Full-Text PDF

Timely Birth Dose Vaccine to Prevent Vertical Transmission of Hepatitis B: A Single Center Experience on the Road to the WHO Elimination Goals in Italy.

Vaccines (Basel) 2021 Jul 19;9(7). Epub 2021 Jul 19.

Pediatric Gastroenterology Unit, AOU Città della Salute e della Scienza di Torino, University of Turin, 10126 Turin, Italy.

Italy was one of the first industrialized countries to implement a program of routine vaccination against hepatitis B virus (HBV) infection. However, currently, no HBV vaccine is administered at birth if the screened mother is HBsAg negative, whilst babies born to HBsAg positive mothers are given vaccine and hepatitis B immunoglobulin, within 12-24 post-delivery hours. A single center retrospective analysis of policies and practices to prevent mother-to-child transmission of HBV was carried out, to evaluate their adherence to HBV care guidelines. Read More

View Article and Full-Text PDF

Prevalence and risk factors of HBV and HCV co-infection among people living with HIV in an Egyptian setting.

Curr HIV Res 2021 Aug 4. Epub 2021 Aug 4.

Tropical Health Department, High Institute of Public Health, Alexandria University, 165 ElHorreya Avenue, Alexandria. Egypt.

Background: Human immune deficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV) infections constitute a global health concern. They share common modes of transmission, increasing the likelihood of co-infection. Co-infection accelerates viral replication, promotes the progression of chronic liver diseases and challenges antiviral therapy. Read More

View Article and Full-Text PDF

Risk of mother-to-child transmission of hepatitis B virus after fetal blood sampling: a report of six cases.

BMC Infect Dis 2021 Jul 30;21(1):716. Epub 2021 Jul 30.

Department of Obstetrics and Gynecology, Third Affiliated Hospital of Sun Yat-sen University, No. 600 Tianhe Road, Tianhe District, Guangzhou, 510630, Guangdong Province, China.

Background: Hepatitis B virus (HBV) remains a major global public health problem worldwide; in endemic areas, mother-to-child transmission (MTCT) of HBV is the most common transmission route. Previous studies have shown that amniocentesis for prenatal diagnosis increases the risk of MTCT of HBV among highly viraemic mothers. However, no data is available on MTCT related fetal blood sampling (FBS) because of the paucity of cases or lack of attention. Read More

View Article and Full-Text PDF

Endemic HBV among hospital in-patients in Bangladesh, including evidence of occult infection.

J Gen Virol 2021 07;102(7)

Department of Microbiology and Infectious Diseases, Oxford University Hospitals NHS Foundation Trust, John Radcliffe Hospital, Headley Way, Headington, Oxford OX1 3SY, UK.

Bangladesh is one of the top-ten most heavily burdened countries for viral hepatitis, with hepatitis B (HBV) infections responsible for the majority of cases. Recombinant and occult HBV infections (OBI) have been reported previously in the region. We investigated an adult fever cohort (=201) recruited in Dhaka, to determine the prevalence of HBV and OBI. Read More

View Article and Full-Text PDF

Management of hepatitis B virus infection in patients with inflammatory bowel disease under immunosuppressive treatment.

World J Gastroenterol 2021 Jul;27(25):3762-3779

GI Unit, 3Academic Department of Internal Medicine, National and Kapodistrian University of Athens, Sotiria Hospital, Athens 11526, Greece.

Hepatitis B remains a significant global clinical problem, despite the implementation of safe and effective vaccination programs. The prevalence of hepatitis B virus (HBV) in patients with inflammatory bowel disease (IBD) largely follows the regional epidemiologic status. Serological screening with hepatitis B surface antigen (HBsAg), and antibodies to hepatitis B surface (anti-HBs) and core (anti-HBc) proteins is a key element in the management of IBD patients and, ideally, should be performed at IBD diagnosis. Read More

View Article and Full-Text PDF

A male-ABCD algorithm for hepatocellular carcinoma risk prediction in HBsAg carriers.

Chin J Cancer Res 2021 Jun;33(3):352-363

State Key Lab of Molecular Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing 100021, China.

Objective: Hepatocellular carcinoma (HCC) development among hepatitis B surface antigen (HBsAg) carriers shows gender disparity, influenced by underlying liver diseases that display variations in laboratory tests. We aimed to construct a risk-stratified HCC prediction model for HBsAg-positive male adults.

Methods: HBsAg-positive males of 35-69 years old (N=6,153) were included from a multi-center population-based liver cancer screening study. Read More

View Article and Full-Text PDF

Do Blood-Borne Viruses Affect the Progression of Labor: A Hospital-Based Pilot Study.

Cureus 2021 Jun 14;13(6):e15631. Epub 2021 Jun 14.

Obstetrics and Gynecology, All India Institute of Medical Sciences, Rishikesh, IND.

Background Blood-borne viruses form the basis of enormous research on universal precautions. A paucity of research is noted regarding labor progression in seropositive women. Women testing positive for human immunodeficiency virus (HIV)/hepatitis B surface antigen (HBsAg)/hepatitis C virus (HCV) are often denied obstetric care and referred. Read More

View Article and Full-Text PDF

Prevention and treatment of new hepatitis B after living donor liver transplantation in children.

Transl Pediatr 2021 Jun;10(6):1610-1617

Department of Liver Transplantation, Tianjin First Center Hospital, Tianjin, China.

Background: This study aimed to explore the prevention and treatment of new hepatitis B in children after liver transplantation with livers positive for HBcAg and to examine the treatment of new hepatitis B.

Methods: A total of 22 children who received livers positive for HBcAg between January 2013 and December 2015 were retrospectively analyzed. After their operations, the children were given lamivudine for anti-hepatitis B virus (HBV) treatment, a hepatitis B vaccine or intermittent supplements of hepatitis B immunoglobulins to prevent recurrence of the infection, and entecavir for anti-hepatitis B treatment. Read More

View Article and Full-Text PDF

Intrahepatic De Novo Tumors in Liver Recipients are Highly Associated With Recurrent Viral Hepatitis.

J Clin Exp Hepatol 2021 Jul-Aug;11(4):435-442. Epub 2020 Nov 25.

Department of Surgery, Campus Charité Mitte | Campus Virchow Klinikum, Charité - Universitätsmedizin Berlin, Corporate Member of Freie Universität Berlin, Humboldt-Universität zu Berlin, and Berlin Institute of Health, Germany.

Background/aims: Long-term survival of liver transplant recipients is endangered by tumorigenesis at different sites. Little is known about primary de novo tumors developing in the graft.

Methods: We analyzed the follow-up data of 2731 liver recipients that were transplanted between 1988 and 2019 at our institution (Charité - Universitätsmedizin Berlin, Department of Surgery). Read More

View Article and Full-Text PDF
November 2020

Poor clinical and virological outcome of nucleos(t)ide analogue monotherapy in HBV/HDV co-infected patients.

Medicine (Baltimore) 2021 Jul;100(28):e26571

Department of Gastroenterology and Hepatology, University Hospital Essen, Germany.

Abstract: Co-infection of Hepatitis B (HBV) and Delta viruses (HDV) represent the most severe form of viral hepatitis. While treatment with pegylated Interferon alpha (PEG-IFNα) is well established, therapy with nucleoside or nucleotide analogues (NA) has been a matter of debate. We aimed to investigate the role of NA treatment in a well-defined single centre cohort. Read More

View Article and Full-Text PDF